Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
51
52
Next >
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
November 10, 2023
Analysts predict Lilly's tirzepatide, marketed under the Mounjaro and Zepbound brands, could achieve peak annual sales of more than $50 billion.
Via
The Motley Fool
Lilly's Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success - Analyst
November 09, 2023
Wednesday, the FDA approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and
Via
Benzinga
Exposures
Product Safety
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
November 09, 2023
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.
Via
Investor's Business Daily
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
November 09, 2023
This competition is leading to a lot of serious innovation.
Via
The Motley Fool
Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
November 09, 2023
Novo Nordisk A/S (NYSE: NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability...
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
November 02, 2023
Via
Benzinga
Why Novo Nordisk Stock Is Surging Higher Today
November 02, 2023
The drugmaker's type 2 diabetes and weight-loss treatment is a growth powerhouse.
Via
The Motley Fool
Earnings Preview For Novo Nordisk
November 01, 2023
Via
Benzinga
Novo Nordisk Unusual Options Activity For October 30
October 30, 2023
Via
Benzinga
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
November 09, 2023
Medicines can sell more when patients understand that they're priced accessibly.
Via
The Motley Fool
Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price
November 08, 2023
The FDA has approved
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
November 08, 2023
Via
Benzinga
Why Novo Nordisk Stock Trounced the Market Today
November 06, 2023
A pair of pundits became notably more bullish on the company in the wake of its latest results announcement.
Via
The Motley Fool
European Pharma Rules Overhaul, Concerns Arise Over Billions In Lost Investment, Undiscovered Treatments
November 06, 2023
The European Federation of Pharmaceutical Industries and Associations (EFPIA)
Via
Benzinga
Why Novo Nordisk Stock Flopped on Friday
November 03, 2023
The news items about the company Friday were two molehills that no investor should make into mountains.
Via
The Motley Fool
Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets
November 03, 2023
Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...
Via
Benzinga
Topics
Bonds
Economy
Exposures
Debt Markets
Interest Rates
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
November 03, 2023
Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic.
Via
The Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in November, and 1 to Avoid
November 03, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a phenomenally cheap industry leader, as well as an exceptionally pricey company...
Via
The Motley Fool
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
November 02, 2023
NVO earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Wegovy Maker Novo Nordisk's Obesity, Diabetes Drug Sales Hit Whopping $22B In Nine Months, Prepares To Expand Capacity
November 02, 2023
Novo Nordisk A/S's (NYSE: NVO) sales for Q3 FY23 climbed 29% Y/Y to DKK
Via
Benzinga
Novo Nordisk Stock Jumps As Wegovy Sales Skyrocket 734%, Crushing Expectations
November 02, 2023
The company's weight-loss drug beat expectations, though sales of diabetes shot Ozempic came in light.
Via
Investor's Business Daily
Weight Watchers Q3 Earnings Preview: Will Ozempic Weigh Down WW Stock?
November 02, 2023
Weight Watchers stock, trading as WW, is already down 30% YTD. Here's what analysts will be watching in the Q3 earnings report.
Via
Benzinga
7 A-Rated Tech Stocks to Buy for November
November 02, 2023
By investing in tech stocks, investors can capitalize on groundbreaking technological advancements and be a part of the future.
Via
InvestorPlace
'AI' Crowned 2023's Word Of The Year, Nudges Out Greedflation, Deinfluencing
November 01, 2023
AI is named the word of the year by a leading dictionary. Find out why and what other words almost beat it.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
November 01, 2023
McKesson earnings are on tap, with Cencora and Cardinal Health due soon.
Via
Investor's Business Daily
These Foods Have An Ozempic-Like Effect And Could Help You Lose Weight
November 01, 2023
GLP-1s, or weight-loss drugs like Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy, are helping millions of Americans manage their weight and diabetes.
Via
Benzinga
Ozempic Supply Is Running Low: Here's Why That Can Be A Problem
October 31, 2023
Ozempic, the diabetes drug also used as a so-called "miracle" weight-loss drug, has been sweeping through America and is now in limited supply.
Via
Benzinga
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
October 31, 2023
Viatris now faces a narrower path to commercializing a generic copy of Ozempic.
Via
The Motley Fool
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
October 29, 2023
Novo Nordisk is planting the seeds to become a competitor in chronic kidney disease therapies.
Via
The Motley Fool
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.